Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/9/2025 | $5.00 | Overweight | Piper Sandler |
| 5/14/2024 | $20.00 | Overweight | Stephens |
| 1/25/2024 | $4.00 | Perform → Outperform | Oppenheimer |
| 11/9/2022 | Buy → Hold | Maxim Group | |
| 11/1/2022 | $2.00 | Neutral → Underperform | BofA Securities |
| 7/19/2022 | $5.00 → $4.00 | Sector Perform | RBC Capital Mkts |
| 5/11/2022 | Outperform → Perform | Oppenheimer | |
| 3/2/2022 | $6.00 → $5.00 | Sector Perform | RBC Capital |
4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)
PLYMOUTH MEETING, Pa., July 7, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting on the potential of next generation DNA medicine technology in rare disease at the upcoming Orphan Drug Summit in Boston, Massachusetts. The conference brings together industry leaders and innovators in the rare disease space to explore the latest developments in technology and manufacturing.
PLYMOUTH MEETING, Pa., July 3, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock and accompanying Series A warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.75 per share of common stock and Series B warrants to purchase up to 14,285,715 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price
PLYMOUTH MEETING, Pa., July 2, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and in either case, accompanying Series A warrants and Series B warrants to purchase shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof), in an underwritten public offering. All of the securities in the proposed offering will be sold by INO
Piper Sandler initiated coverage of Inovio Pharma with a rating of Overweight and set a new price target of $5.00
Stephens initiated coverage of Inovio Pharma with a rating of Overweight and set a new price target of $20.00
Oppenheimer upgraded Inovio Pharma from Perform to Outperform and set a new price target of $4.00
8-K - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
424B5 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
424B5 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)
LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company's clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Bogatyrenko will add additional strength to the Group's business development strategy. Dr. Liebowitz is a seasoned hematologist-oncologist and drug development leader with more than 30 years of experience across academia and indust
PLYMOUTH MEETING, Pa., Jan. 9, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today highlighted anticipated milestones for 2025 and key accomplishments from 2024 in advance of upcoming investor meetings. "Based on the progress achieved in 2024, we anticipate 2025 to be a transformational year for INOVIO as we move closer to our goal of becoming a commercial-stage company providing a breakthrough therapy for pati
Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa., July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer. Mr. Egge will le
On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25Clinical and immunological results from Phase 1/2 trial of INO-3107 published in Nature Communications in February 2025INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with significant clinical benefit as measured by reduced need for surgeryAnnounced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encod
PLYMOUTH MEETING, Pa., April 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that first quarter 2025 financial results will be released after the market close on May 13, 2025. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update. The live webcast will be available online at http://ir.in
Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) Resolved previously announced manufacturing issue concerning the single-use array component of the CELLECTRA device and completed drafting of all non-device BLA modules On track to begin rolling submission of BLA in mid-2025 and to request priority review with goal of completing the submission in the second half of 2025 and receiving acceptance of the submission by end of the yearAnnounced durability data from retrospective study showing that 50% of patients achieved a Complete Response in the second 12-month period (year 2) with 86
SC 13G - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)
SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)
SC 13G/A - INOVIO PHARMACEUTICALS, INC. (0001055726) (Subject)